PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
The relevance of PCSK9 in atherosclerosis progression is demonstrated by the benefits observed in patients that have followed PCSK9-targeted therapies. The impact of these therapies is attributed to the plasma lipid-lowering effect induced when LDLR hepatic expression levels are recovered after the suppression of soluble PCSK9. Different studies show that PCSK9 is involved in other mechanisms that take place at different stages during atherosclerosis development. Indeed, PCSK9 regulates the expression of key receptors expressed in macrophages that contribute to lipid-loading, foam cell formation and atherosclerotic plaque formation. PCSK9 is also a regulator of vascular inflammation and its expression correlates with pro-inflammatory cytokines release, inflammatory cell recruitment and plaque destabilization. Furthermore, anti-PCSK9 approaches have demonstrated that by inhibiting PCSK9 activity, the progression of atherosclerotic disease is diminished. PCSK9 also modulates thrombosis by modifying platelets steady-state, leukocyte recruitment and clot formation. In this review we evaluate recent findings on PCSK9 functions in cardiovascular diseases beyond LDL-cholesterol plasma levels regulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634 · cited 1×
“The ODYSSEY OUTCOMES study in patients with recent acute coronary syndrome at maximum tolerated dose of statins showed that alirocumab administration was associated with a reduced risk of recurrent ischemic cardiovascular events and also with a reduced mortality (24).”
MethodToll-like receptors in innate immunity
Takeda, K. (2004) · International Immunology · doi:10.1093/intimm/dxh186 · Cited by 3,328 · cited 1×
“TLRs are cell receptors that recognize pathogens and regulate the expression of pro-inflammatory cytokines and also the early immune responses to infection (63).”
BackgroundMutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
Mechanisms of plaque formation and rupture
Bentzon, J. F., Otsuka, F., Virmani, R., & Falk, E. (2014) · Circulation Research · doi:10.1161/circresaha.114.302721 · Cited by 2,391
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296 · cited 1×
“They were tested in the OSLER trial (21) and in the ODYSSEY LONG TERM trial (22), respectively (Table 1).”
MethodCirculating endothelial progenitor cells and cardiovascular outcomes
Werner, N., Kosiol, S., Schiegl, T., Ahlers, P., Walenta, K., Link, A., Böhm, M., & Nickenig, G. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043814 · Cited by 2,048
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Ray, K. K., Wright, R. S., Kallend, D., Koenig, W., Leiter, L. A., Raal, F. J., Bisch, J. A., Richardson, T., Jaros, M., Wijngaard, P. L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1912387 · Cited by 1,665 · cited 1×
“Inclisiran (a small interference RNA) and statin administration in patients with atherosclerotic cardiovascular disease or heterozygous hypercholesterolemia patients reduced PCSK9 levels in blood and LDL-cholesterol levels in ORION-9 and ORION-10/ORION-11 phase 3 clinical trials (26, 27).”
BackgroundEfficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500858 · Cited by 1,509
Chatzizisis, Y. S., Coskun, A. U., Jonas, M., Edelman, E. R., Feldman, C. L., & Stone, P. H. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.059 · Cited by 1,483 · cited 1×
“Vascular cells are affected by hemodynamic factors like blood flow that, by inducing wall shear stress, play a critical role in atherosclerosis development and progression (59).”
BackgroundSeidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., & Chrétien, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0335507100 · Cited by 1,191
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Raal, F. J., Kallend, D., Ray, K. K., Turner, T., Koenig, W., Wright, R. S., Wijngaard, P. L. J., Curcio, D., Jaros, M. J., Leiter, L. A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913805 · Cited by 818 · cited 1×
“Inclisiran (a small interference RNA) and statin administration in patients with atherosclerotic cardiovascular disease or heterozygous hypercholesterolemia patients reduced PCSK9 levels in blood and LDL-cholesterol levels in ORION-9 and ORION-10/ORION-11 phase 3 clinical trials (26, 27).”
BackgroundZhang, D.-W., Lagace, T. A., Garuti, R., Zhao, Z., McDonald, M., Horton, J. D., Cohen, J. C., & Hobbs, H. H. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702027200 · Cited by 788 · cited 1×
“In 2007, PCSK9 was found to be a ligand for Low Density Lipoprotein Receptor (LDLR) a key cell membrane receptor in cholesterol homeostasis regulation (2).”
BackgroundCardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
Ridker, P. M., Revkin, J., Amarenco, P., Brunell, R., Curto, M., Civeira, F., Flather, M., Glynn, R. J., Gregoire, J., Jukema, J. W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701488 · Cited by 624 · cited 1×
“The negative results concluded in a premature stop of the trial by the sponsor (25).”
BackgroundJNK promotes Bax translocation to mitochondria through phosphorylation of 14‐3‐3 proteins
Tsuruta, F., Sunayama, J., Mori, Y., Hattori, S., Shimizu, S., Tsujimoto, Y., Yoshioka, K., Masuyama, N., & Gotoh, Y. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600194 · Cited by 556 · cited 1×
“Interestingly, p38 and JNK are also responsible of Bax and Bad phosphorylation that activate programmed cell death (73, 74).”
BackgroundHow it all starts: Initiation of the clotting cascade
Smith, S. A., Travers, R. J., & Morrissey, J. H. (2015) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2015.1050550 · Cited by 529
Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer
Liu, X., Bao, X., Hu, M., Chang, H., Jiao, M., Cheng, J., Xie, L., Huang, Q., Li, F., & Li, C.-Y. (2020) · Nature · doi:10.1038/s41586-020-2911-7 · Cited by 490 · cited 1×
“Therefore, PCSK9 decreases the cytotoxic T lymphocyte response against the tumor (90).”
BackgroundPoirier, S., Mayer, G., Benjannet, S., Bergeron, E., Marcinkiewicz, J., Nassoury, N., Mayer, H., Nimpf, J., Prat, A., & Seidah, N. G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708098200 · Cited by 477 · cited 2×
“Indeed, treatment of HEK293 cells or 3T3 fibroblasts cells with human recombinant PCSK9 shows a downregulation of VLDLR expression levels (54).”
BackgroundGuijarro-Muñoz, I., Compte, M., Álvarez-Cienfuegos, A., Álvarez-Vallina, L., & Sanz, L. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.521161 · Cited by 342
Resistance and intolerance to statins
Reiner, Ž. (2014) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2014.05.009 · Cited by 225 · cited 1×
“However, some patients present statin intolerance which hampers the treatment (12).”
BackgroundKühnast, S., van der Hoorn, J. W. A., Pieterman, E. J., van den Hoek, A. M., Sasiela, W. J., Gusarova, V., Peyman, A., Schäfer, H.-L., Schwahn, U., Jukema, J. W., et al. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m051326 · Cited by 204
Chen, K., Febbraio, M., Li, W., & Silverstein, R. L. (2008) · Circulation Research · doi:10.1161/circresaha.108.172064 · Cited by 202
PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway
Wu, C.-Y., Tang, Z.-H., Jiang, L., Li, X.-F., Jiang, Z.-S., & Liu, L.-S. (2012) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-011-1028-6 · Cited by 190 · cited 1×
“Lipid loaded endothelial cells show increased Bax protein levels and decreased Bcl-2 levels that lead to caspase 3 and caspase 9 activation inducing cell apoptosis (68).”
BackgroundPCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages
Ding, Z., Liu, S., Wang, X., Theus, S., Deng, X., Fan, Y., Zhou, S., & Mehta, J. L. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy079 · Cited by 147 · cited 5×
“This increased lipid uptake is abolished in macrophages that lack SRA, CD36, or LOX-1 suggesting that all three receptors are involved in oxLDL uptake and consequently, in the generation of foam cells in atherosclerosis (50).”
BackgroundInfluentialInhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages
Adorni, M. P., Cipollari, E., Favari, E., Zanotti, I., Zimetti, F., Corsini, A., Ricci, C., Bernini, F., & Ferri, N. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.11.019 · Cited by 130 · cited 1×
“Also, ABCA1 protein, a protein responsible for cholesterol efflux in macrophages, was inhibited upon PCSK9 expression (94).”
BackgroundHofmann, A., Brunssen, C., & Morawietz, H. (2018) · Vascular Pharmacology · doi:10.1016/j.vph.2017.10.002 · Cited by 68
Unexpected roles for PCSK9 in lipid metabolism
Soutar, A. K. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834622b5 · Cited by 39
Cited by
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): From bench to bedside
Bao, X., Liang, Y., Chang, H., Cai, T., Feng, B., Gordon, K., Zhu, Y., Shi, H., He, Y., & Xie, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01690-3 · Cited by 187
Targeting PCSK9 to tackle cardiovascular disease
Hummelgaard, S., Vilstrup, J. P., Gustafsen, C., Glerup, S., & Weyer, K. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108480 · Cited by 150
Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis
Punch, E., Klein, J., Diaba‐Nuhoho, P., Morawietz, H., & Garelnabi, M. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.023328 · Cited by 101
PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology
Sundararaman, S. S., Döring, Y., & van der Vorst, E. P. C. (2021) · Biomedicines · doi:10.3390/biomedicines9070793 · Cited by 67
Wang, W.-L., Shih, Y.-T., Wei, S.-Y., & Chiu, J.-J. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01177-z · Cited by 50
“PCSK9 inhibitors, in addition to stabilizing LDL receptors (LDLRs) to lower LDL-C [253], also protect EC function by reducing inflammation and oxidative stress, thus attenuating plaque vulnerability [254].”
Metadata
- Authors
- Luquero, A., Badimon, L., & Borrell-Pages, M.
- Venue
- Frontiers in Cardiovascular Medicine
- Publisher
- Frontiers Media SA
- Published
- 2021-03-23
- Volume
- 8
- Pages
- 639727-639727
- ISSN
- 2297-055X (ISSN-L)
- OpenAlex
- W3139036322
- Cited by
- 73
- References
- 27
- FWCI
- 9.96
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.